Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Shigella sonnei strain 53G
- Development stage
- Phase 1
- Lead developer
- Walter Reed Army Institute of Research
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Shigella sonnei strain 53G is a well-characterized laboratory and clinical challenge strain of the Gram-negative bacterium *Shigella sonnei*, which is a major cause of bacillary dysentery (shigellosis) worldwide[1][3][5]. Strain 53G belongs to lineage II and has been widely used in controlled human infection models (CHIMs) for vaccine development and pathogenesis studies[1][3][6]. The organism possesses a virulence plasmid (pINV) encoding a type III secretion system essential for host cell invasion and disease manifestation[2]. Lyophilized preparations of this specific strain have been produced under current good manufacturing practice (cGMP) standards for use in standardized human challenge studies[3][6]. Infection with this challenge organism reliably induces shigellosis symptoms such as diarrhea, fever, and abdominal pain in healthy adult volunteers at defined doses; it serves as an important tool to evaluate candidate vaccines and study host-pathogen interactions[5][8].
- Other names
- Shigella sonnei strain 53GS. sonnei strain 53GSonne's bacillus (historical)
Beyond the preview
Go deeper on Shigella sonnei strain 53G.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shigella sonnei strain 53G.